Deutsche Bank raised the firm’s price target on CVS Health (CVS) to $70 from $66 and keeps a Buy rating on the shares. The company issued a positive narrative for 2025, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health Corp’s Mixed Earnings Call Highlights Growth and Challenges
- CVS Health price target raised to $76 from $60 at Truist
- Target downgraded, Cisco upgraded: Wall Street’s top analyst calls
- CVS Health price target raised to $75 from $63 at BofA
- Optimistic Future for CVS Health: Strong Q4 2024 Performance and Promising 2025 Outlook